Insider Selling: Marinus Pharmaceuticals Inc (MRNS) CEO Sells 9,566 Shares of Stock
Marinus Pharmaceuticals Inc (NASDAQ:MRNS) CEO Christopher Michael Cashman sold 9,566 shares of the company’s stock in a transaction on Thursday, January 18th. The shares were sold at an average price of $6.28, for a total value of $60,074.48. Following the completion of the sale, the chief executive officer now owns 247,903 shares in the company, valued at $1,556,830.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Marinus Pharmaceuticals Inc (NASDAQ MRNS) traded up $0.71 during midday trading on Monday, reaching $7.54. The company had a trading volume of 2,363,181 shares, compared to its average volume of 1,850,000. Marinus Pharmaceuticals Inc has a 1 year low of $1.06 and a 1 year high of $9.87. The stock has a market capitalization of $305.25, a P/E ratio of -8.11 and a beta of 2.44.
Marinus Pharmaceuticals (NASDAQ:MRNS) last released its earnings results on Tuesday, October 31st. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.17) by $0.02.
Several analysts have recently issued reports on MRNS shares. BidaskClub upgraded Marinus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, December 30th. Laidlaw started coverage on Marinus Pharmaceuticals in a research report on Thursday, December 14th. They issued a “buy” rating and a $18.00 price objective on the stock. Finally, ValuEngine downgraded Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, December 1st.
Marinus Pharmaceuticals Company Profile
Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.